2nd Quarter - Termination
MICHAEL BEST STRATEGIES LLC for SAREPTA THERAPEUTICS
Client
Income
$50,000
Expenses
—
Terminated
May 12, 2026
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAMI JACKSON BUCKNER | — |
| NINIO FETALVO | — |
| MEGAN SARA SHELINE | — |
| BRITTAN SPECHT | — |
Medical/Disease Research/Clinical Labs MED
Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAMI JACKSON BUCKNER | — |
| NINIO FETALVO | — |
| MEGAN SARA SHELINE | — |
| BRITTAN SPECHT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.